Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    porciatti
Previous Study | Return to List | Next Study

Stop Retinal Ganglion Cell Dysfunction Study (STOP-RGCD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by University of Miami
National Eye Institute (NEI)
Information provided by (Responsible Party):
Vittorio Porciatti, University of Miami Identifier:
First received: March 10, 2015
Last updated: October 17, 2016
Last verified: October 2016
Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease, predicting its severity and the benefit of pressure lowering eye drops is key to clinical management aimed at maintaining useful vision with advancing age. This study will longitudinally monitor a population of glaucoma suspects (with positive factors for the disease but with normal vision) with noninvasive pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) that are the parent neurons of the optic nerve. RGCs may become dysfunctional before dying and their function restored with pressure-lowering eye drops. Glaucoma suspects with abnormal PERG will be randomized to treatment with eye drops, while those with normal PERG will be left untreated. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests every 6 months over 4 years.

Condition Intervention Phase
Drug: Latanoprost
Drug: Bimatoprost
Drug: Travoprost
Drug: Timolol
Drug: Dorzolamide
Drug: Brinzolamide
Drug: Acetazolamide
Drug: Methazolamide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Stop Retinal Ganglion Cell Dysfunction Study

Resource links provided by NLM:

Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Retinal Nerve Fiber Layer Thickness change through Optical Coherence Tomography evaluation [ Time Frame: 4 years ]
    To know Retinal Nerve Fiber Layer thickness changes from Baseline to 4 years follow up through Optical Coherence Tomography evaluation.

Secondary Outcome Measures:
  • Pattern Electroretinogram Changes [ Time Frame: 4 years ]
    To know Pattern Electroretinogram amplitude (micro-volts) and phase (degrees) changes from Baseline to 4 years follow up through Pattern Electroretinogram evaluation.

Estimated Enrollment: 500
Study Start Date: September 2014
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Abnormal PERG Untreated
Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to not receive therapy or intervention.
Experimental: Abnormal PERG Treated

Participants recognized as Glaucoma suspects with an abnormal PERG test who have been assigned to receive one or more drops in each eye in order to reduce the intraocular pressure by 20%.

Drugs could be:

Latanoprost 1 drop Once a day (QD) Bimatoprost 1 drop QD Travoprost 1 drop QD Timolol 1 drop Twice a day (BID) Dorzolamide 1 drop Three times a day (TID) Brinzolamide 1 drop BID Acetazolamide and Methazolamide depends on clinicians evaluation.

If Clinicians consider necessary, he/she might combine 2 drugs in order to get the desired intraocular pressure.

Drug: Latanoprost
Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
Other Name: Xalatan
Drug: Bimatoprost
Lower intraocular pressure by increasing outflow of fluid from the eye.
Other Name: Lumigan
Drug: Travoprost
Lower intraocular pressure by increasing outflow of fluid from the eye.
Other Name: Travatan
Drug: Timolol
Lower intraocular pressure by decreasing production of fluid
Other Name: Timoptic
Drug: Dorzolamide
Lowers intraocular pressure by decreasing intraocular fluid production
Other Name: Trusopt
Drug: Brinzolamide
Lowers intraocular pressure by decreasing intraocular fluid production
Other Name: Azopt
Drug: Acetazolamide
Lowers intraocular pressure by decreasing intraocular fluid production
Other Name: Diamox
Drug: Methazolamide
Lowers intraocular pressure by decreasing intraocular fluid production
Other Name: Neptazane
No Intervention: Normal
Patients with a normal PERG test that will go through the study under observation.

Detailed Description:

The PERG is recorded from small metallic buttons taped on the skin similarly to an electrocardiogram, with the difference that the electrodes are around the eyes.

The only physical contact you will experience is a gentle cleaning of the skin with an alcohol prep pad. During the test you must look with both eyes at a Television (TV) display for about 3 minutes. During the follow up period you may be asked to take one more PERG test lying down in a bed.

This will cause a momentary increase of your eye pressure similar to the one that occurs during your normal sleep. This may help to understand whether or not your optic nerve functions normally when the pressure in your eye increases. For OCT evaluation, the pupil has to be dilated with drops as you did before for your eye exam. You have to briefly look at a mark inside the instrument one eye at a time.

PERG and OCT will be performed during the same day of your visit with the eye doctor. If you have already done these tests in the past, as part of another study or as part of your standard treatment, the results of these tests will be obtained from your record, and be included in this study.

If you are a participant in the Observation Group, you will be monitored with PERG, OCT, and standard clinical examinations every six months until close of study. If you are a participant in the Medication Group you will be also treated with eye drop medicines.


There are certain risks and discomforts that may be associated with this research. You should be aware that you are at risk of developing glaucoma whether you participate in the study or not. It is not known whether the risk of developing glaucoma is reduced by eye drops to lower eye pressure; the study will attempt to answer this question.

For the PERG, the only significant risk to you is a small chance of a rash to the cleansing agent for skin electrodes, which should go away without treatment. For OCT, there is a rare risk to you of an allergic reaction to the drops used to dilate your pupils. The risk is even lower if you did not have any reaction during your previous eye exams. In case of an allergic reaction, your eye doctor will immediately treat it. If you had previous problems with pupil dilation, you may wish to speak to your eye doctor about the option of doing this additional test.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age 18 to 85 years, inclusive
  2. Refractive errors within -5 to +3 diopters
  3. Best corrected visual acuity (BCVA) better than or equal to 20/30 (Snellen)
  4. Normal standard automated perimetry (SAP) according to the Ocular Hypertension Treatment Study (OHTS) criteria15 (reliability < 15% on all indices, normality > 5% on all global indices in two consecutive sessions 6 months apart)
  5. Minimum untreated Intraocular pressure IOP of 15 mm Hg
  6. Glaucoma Suspect Status defined as one or more of the following:

    • Glaucomatous optic disc appearance (vertical cup-to-disc ratio [C/D] ≥0.5
    • Cup disc ratio asymmetry ≥0.2
    • Localized thinning of the disc
    • Presence or history of splinter disc hemorrhage
    • Moderately increased IOP (>21 to <28 mm Hg).
    • Family history of vision loss for glaucoma

Exclusion Criteria:

  1. Age-related macular degeneration
  2. Diabetes
  3. Parkinson's disease
  4. Multiple sclerosis
  5. Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits.
  6. Pregnant or nursing women.
  7. Currently using prescribed pressure lowering medicines and unwilling to be withdrawn from them.
  8. An OHTS risk score high enough in the judgment of the ophthalmologist or optometrist managing the patient to recommend pressure lowering medicine to the patient and not randomization.
  9. An OCT abnormal enough in a pattern consistent with glaucoma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02390284

Contact: Marlene Colon, RC 305 482 4309
Contact: Pedro Monsalve, RA 305 482 4309

United States, Florida
Bascom Palmer Eye Institute - University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Marlene Perez, RC    305-482-4309   
Contact: Pedro Monsalve, RA    305 482 4309   
Principal Investigator: Vittorio Porciatti, DSc         
Sub-Investigator: John J McSoley, OD         
Sub-Investigator: Luis E Vazquez, MD,PhD         
Sub-Investigator: Steven J Gedde, MD         
Sub-Investigator: Giacinto Triolo, RF         
Sub-Investigator: Pedro F Monsalve, RA         
Sponsors and Collaborators
University of Miami
National Eye Institute (NEI)
Principal Investigator: Vittorio Porciattti, DSc University of Miami
  More Information

Responsible Party: Vittorio Porciatti, Professor, University of Miami Identifier: NCT02390284     History of Changes
Other Study ID Numbers: 20140587
R01EY014957 ( US NIH Grant/Contract Award Number )
Study First Received: March 10, 2015
Last Updated: October 17, 2016

Keywords provided by University of Miami:
Glaucoma Suspect

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Antihypertensive Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Anti-Arrhythmia Agents processed this record on April 27, 2017